[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576812":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":35,"collaborators":37,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":20,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Texas Tech University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients undergoing obesity treatment",null,"This cohort will be comprised of individuals who are beginning obesity medication treatment at a specified virtual obesity medicine practice. Patients taking semaglutide or tirzepatide may be eligible for inclusion in this cohort.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Grant Tinsley, Ph.D.","CONTACT","806-834-5895","grant.tinsley@ttu.edu",[19],{"facility":5,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"RECRUITING","Lubbock","Texas","79409","United States","US",{"type":27,"coordinates":28},"Point",[29,30],-101.85517,33.57786,{"lat":30,"lon":29},[33],{"name":34,"role":15,"phone":16,"phoneExt":10,"email":17},"Grant Tinsley",{"type":36,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[38],{"name":39,"class":40},"Vineyard Health Inc.","UNKNOWN","100576812","study-of-patients-being-treated-with-anti-obesity-medication-100576812",false,"NCT06790160","Study of Patients Being Treated With Anti-obesity Medication","Observational Study of Patients Being Treated With Anti-obesity Medication","Inclusion Criteria:\n\n* Patient who is beginning treatment through Vineyard Virtual Health Clinic using semaglutide or tirzepatide. While the physician will individualize the treatment plans, the criteria for these medications will include, at a minimum: (A) a body mass index ≥30 kg\u002Fm2; OR (B) a BMI ≥27 kg\u002Fm2 plus at least one comorbidity.\n* Patient who lives in drivable proximity to a city with an accepted DXA testing facility and is willing to report to the facility for periodic body composition testing.\n\nExclusion Criteria:\n\n* Patients with type 2 diabetes.\n* Patients who report not being willing or able to complete the assessments included in this research study.\n* Patients who are currently pregnant or trying to become pregnant.","ALL","18 Years",{"count":51,"type":52},100,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the real-world effects of selected obesity medications in adults undergoing medical weight management. The main outcomes of interest are changes in body composition, routine clinical markers, muscular performance, and nutritional intake over the course of treatment. Additionally, the influence of lifestyle factors on changes in these outcome variables will be examined.\n\nParticipants beginning treatment with selected obesity medications will undergo periodic body composition and muscular performance testing, as well as complete online surveys about their nutritional intake and physical activity and exercise participation. Additionally, routinely collected clinical information will be evaluated.",[56],"Obesity and Overweight",[58,59,60,61,62],"obesity","GLP-1","body composition","nutrition","exercise","2026-05-13",{"date":65,"type":66},"2026-05-15","ACTUAL",{"date":68,"type":66},"2025-01-31",{"date":70,"type":52},"2027-12",{"name":5,"class":6},1]